N-(4-acetyl-1-piperazinyl) -4-fluorobenzamide monohydrate

10/01/2002 - "These results demonstrate that FK960 is more efficacious than CEIs in improving memory deficits, and that FK960 has synergistic efficacy when combined with CEIs."
06/01/1998 - "Ohkubo, I. Yamaguchi, FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action, J. "
12/01/1996 - "FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action."
10/01/2002 - "FK960 (0.1-10 mg/kg ip) significantly ameliorated the memory deficits in all three models. "
01/01/2004 - "N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, has been demonstrated to ameliorate memory deficits in various experimental models of dementia. "

12/27/2002 - "FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel anti-dementia drug, has been shown to ameliorate experimental amnesia in rats and monkeys through activation of the somatostatinergic nervous system in the hippocampus. "
12/27/2002 - "Furthermore, FK960 has been shown to be considerably more effective in a model of spontaneous amnesia in aged rats than cholinesterase inhibitors. "
06/01/1998 - "Our previous studies have demonstrated that FK960 (FR59960; N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate), a novel antidementia piperazine derivative, exerts beneficial effects on memory deficits in various animal models of amnesia in rats [M. "
03/01/1997 - "Our previous studies demonstrated that FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel antidementia piperazine derivative, exerts beneficial effects on memory deficits in various rodent models of amnesia, through activation of the somatostatin neuronal system. "

12/30/2002 - "The present study was conducted to understand the mechanism underlying the facilitatory action of FK960, an anti-dementia drug, on hippocampal neurotransmission. "
12/27/2002 - "FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats."
06/01/1998 - "FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices."
01/01/2004 - "N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, has been demonstrated to ameliorate memory deficits in various experimental models of dementia. "
12/27/2002 - "FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel anti-dementia drug, has been shown to ameliorate experimental amnesia in rats and monkeys through activation of the somatostatinergic nervous system in the hippocampus. "

01/01/2004 - "The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease."
01/01/2012 - "In this study, benzothiazole-piperazine compounds were synthesized by condensing the functional groups of donepezil (DNP), FK-960, and sabeluzole, which are known to have therapeutic potential against Alzheimer's disease, with the aim of obtaining new and potent anti-Alzheimer agents. "

12/01/1996 - "From these results, we conclude that FK960 ameliorates cognitive dysfunction through an activation of the somatostatinergic-serotonergic link."
01/01/2004 - "Thus, the activation of somatostatinergic neurotransmission, with FK960 or a similar drug, has considerable potential in the treatment of cognitive impairment."